GH1 and rhabdomyosarcoma: Given concerns about GH therapy's potential cancer risks (Bamba and Kanakatti Shankar 2022) and CDKN1C's association with malignancies in BWS, caution is warranted, though no malignancy link is established for IMAGe syndrome beyond a single rhabdomyosarcoma case (Bolomiti et al. 2021).